Heron Therapeutics | HRTX - Beneficio Bruto En Ventas

Precio De Mercado
1.06
Cambio Diario
-0.07 -6.19%
Mensual
-12.40%
Anual
-55.83%
Q1 Expectativa
1.15




Beneficio Bruto En Ventas Cambio Fecha
ALKERMES USD 338.34M 72.51M 2025-12
Alnylam Pharmaceuticals USD 829.31M 219.56M 2025-12
Amarin USD 22.21M 28.15M 2025-09
ANI Pharmaceuticals USD 124.18M 12.39M 2025-12
Anika Therapeutics USD 14.68M 9.46M 2025-03
Arrowhead Research USD 256.47M 228.7M 2025-09
Eisai JPY 168.85B 17.02B 2025-12
Esperion Therapeutics USD -29.52M 32.4M 2024-09
GlaxoSmithKline GBP 6.18B 106M 2025-12
Heron Therapeutics USD 23.35M 1.6M 2024-09
Insmed USD 217.69M 106.25M 2025-12
Ligand Pharmaceuticals USD 155.28M 82.42M 2025-09
Merck USD 13.42B 431M 2025-09
Nektar Therapeutics USD 13.75M 650K 2024-06
Neurocrine Biosciences USD 787.9M 7M 2025-12
Omeros USD -33.16M 18.52M 2024-06
Pacira USD 142.25M 11.34M 2025-12
Regeneron Pharmaceuticals USD 3.3B 67M 2025-12
Roche Holding CHF 22.09B 10.04B 2025-12
Sangamo BioSciences -2.39M 1.09M 2024-06
Surmodics USD -11.54M 3.99M 2024-09
Ultragenyx Pharmaceutical USD 178M 46.06M 2025-12
Veracyte USD 101.97M 10.69M 2025-12
Vertex Pharmaceuticals USD 2.72B 62.4M 2025-12